Removal of mtDNA in Plasma by Continous Venovenous Hemofiltration in Sepsis
NCT ID: NCT04083482
Last Updated: 2019-09-10
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
UNKNOWN
NA
20 participants
INTERVENTIONAL
2018-08-20
2019-12-31
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Safety and Efficiency of Combined Extracorporeal Blood Purification in Neurosurgical ICU. Prospective RCT
NCT04152174
The Effect of rTEM in the Prognosis and Severity of Sepsis Induced ARDS
NCT06063707
Unfractioned Heparin for Treatment of Sepsis Caused by Abdominal Infection
NCT04861922
Mitochondrial Function in Septic Patients
NCT03748537
Blood Purification in Septic Children
NCT05595239
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
NA
SINGLE_GROUP
TREATMENT
NONE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Septic patients require CVVH
continuous venovenous hemofiltration. Continuous renal replacement therapy（CRRT）has become routine for patients with chronic renal failure ，AKI，fliud overload as well as oliguria in ICU .Continuous venovenous hemofiltration（CVVH）is the method of chioce for CRRT in critical ill .CVVH has significant beneficial effects on removing inflammatory cytokines ，improving oxygen index ，decreasing vasopressor requirements，increasing cardiac index and regulating immune dysfunction .
continous venovenous hemofiltraion
CVVH
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
continous venovenous hemofiltraion
CVVH
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
Exclusion Criteria
2. transplatation
3. cancer
4. aquired immunodeficiency syndrome
18 Years
ALL
Yes
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
First People's Hospital of Chenzhou
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Xingui Dai
Critical Care Medicine
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
dixian luo, MS
Role: STUDY_DIRECTOR
Chenzhou First people Hospital
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
The First Hospital of Chenzhou
Chenzhou, Hunan, China
Countries
Review the countries where the study has at least one active or historical site.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
WYJ2019
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.